Arana expands clinical research

By Kate McDonald
Monday, 28 July, 2008

Arana Therapeutics (ASX: AAH) has appointed former Quintiles executive Dr Alan Scott as its new vice president of clinical research.

The Sydney-headquartered biotech, the result of a merger between Peptech and EvoGenix last year, is commencing several new clinical trials in the next 18 months.

Arana's next scheduled clinical trial will be a Phase II rheumatoid arthritis dose-ranging study for its leading anti-inflammatory compound ART621, which is expected to start in the fourth quarter of this year.

Scott holds a PhD from Glasgow University, did a post-doc in biochemistry at Oxford and has held positions in clinical operations and project management in Europe in the pharma, biotech and CRO sectors.

He was director of site start up for Quintiles in the Asia-Pacific region.

Related News

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd